Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitis compared to ACR/EULAR 2022 classification criteria.
Sada KE, Nagasaka K, Kaname S, Higuchi T, Furuta S, Nanki T, Tsuboi N, Amano K, Dobashi H, Hiromura K, Bando M, Wada T, Arimura Y, Makino H, Harigai M. Sada KE, et al. Among authors: amano k. Mod Rheumatol. 2024 Mar 28;34(3):551-558. doi: 10.1093/mr/road052. Mod Rheumatol. 2024. PMID: 37279574
Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; Real Study Group. Sakai R, et al. Among authors: amano k. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125-34. doi: 10.1002/acr.21666. Arthritis Care Res (Hoboken). 2012. PMID: 22422487 Free article.
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group. Sakai R, et al. Among authors: amano k. Ann Rheum Dis. 2012 Nov;71(11):1820-6. doi: 10.1136/annrheumdis-2011-200838. Epub 2012 Apr 13. Ann Rheum Dis. 2012. PMID: 22504558 Free article.
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Kurasawa T, Nagasawa H, Kishimoto M, Amano K, Takeuchi T, Kameda H. Kurasawa T, et al. Among authors: amano k. Mod Rheumatol. 2014 Jul;24(4):561-6. doi: 10.3109/14397595.2013.844886. Epub 2013 Nov 5. Mod Rheumatol. 2014. PMID: 24252035 Free article. Clinical Trial.
A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan.
Sada KE, Amano K, Uehara R, Yamamura M, Arimura Y, Nakamura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour, Welfare of Japan. Sada KE, et al. Among authors: amano k. Mod Rheumatol. 2014 Jul;24(4):640-4. doi: 10.3109/14397595.2013.857582. Epub 2013 Dec 2. Mod Rheumatol. 2014. PMID: 24289197
The efficacy of mizoribine for the treatment of rheumatoid arthritis and its correlation with renal function.
Terai C, Tsutsumi T, Sakurai T, Moriguchi M, Azuma T, Kaneko M, Kawagoe M, Hoshi K, Yoshida H, Matsui T, Nakajima K, Okuyama A, Nishi E, Amano K, Ota M, Mimura T, Chino K, Aoki K, Handa Y, Hirose T, Kida I, Kobayashi S, Suzuki K, Matsuzaki T, Kuga Y. Terai C, et al. Among authors: amano k. Mod Rheumatol. 2014 Nov;24(6):892-6. doi: 10.3109/14397595.2014.885376. Epub 2014 Mar 4. Mod Rheumatol. 2014. PMID: 24593172
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
Sakai R, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M; REAL study group. Sakai R, et al. Among authors: amano k. Rheumatol Int. 2014 Dec;34(12):1729-36. doi: 10.1007/s00296-014-3045-8. Epub 2014 May 23. Rheumatol Int. 2014. PMID: 24852650
Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
Amano K, Matsubara T, Tanaka T, Inoue H, Iwahashi M, Kanamono T, Nakano T, Uchimura S, Izumihara T, Yamazaki A, Karyekar CS, Takeuchi T; Japan Abatacept Study Group. Amano K, et al. Mod Rheumatol. 2015 Sep;25(5):665-71. doi: 10.3109/14397595.2015.1012786. Mod Rheumatol. 2015. PMID: 25698370 Free article.
1,360 results